Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTOLERANCE TO NEUROLEPTIC DRUGS - THE ART OF AVOIDING EXTRAPYRAMIDALSYNDROMES
Autore:
GERLACH J; PEACOCK L;
Indirizzi:
ST HANS HOSP,BIOL PSYCHIAT RES INST,DEPT P DK-4000 ROSKILDE DENMARK
Titolo Testata:
European psychiatry
, volume: 10, anno: 1995, supplemento:, 1
pagine: 27 - 31
SICI:
0924-9338(1995)10:<27:ITND-T>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Keywords:
EXTRAPYRAMIDAL SYMPTOMS; DYSTONIA; DYSKINESIA; PARKINSONISM; AKATHISIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
NO
Recensione:
Indirizzi per estratti:
Citazione:
J. Gerlach e L. Peacock, "INTOLERANCE TO NEUROLEPTIC DRUGS - THE ART OF AVOIDING EXTRAPYRAMIDALSYNDROMES", European psychiatry, 10, 1995, pp. 27-31

Abstract

Akathisia, dystonia, dyskinesia and parkinsonism, the four main categories of neuroleptic-induced extrapyramidal syndromes (EPS), representmajor disadvantages in antipsychotic therapy. In vulnerable patients,acute EPS may progress into potentially irreversible forms such as tardive dystonia and tardive dyskinesia. In the psychiatric clinic, these EPS are often insufficiently recognised or permitted to exist without treatment. In order to ensure a better EPS diagnosis, a simple examination procedure is described. EPS rating scales may serve as an aid in this process. Guidelines are given to prevent and treat EPS. Thus, EPS are best prevented by a course of neuroleptic medication involving as little antidopaminergic D-2 effect as possible, including the use of the lowest effective dose (sometimes obtained by addition of a benzodiazepine or carbamazepine) and with antipsychotic drugs which producelow D? receptor blockade. Treating EPS also consists of using the lowest effective dose and antipsychotics with a low D-2 dopamine receptoroccupancy. At present, clozapine is the only drug that produces antipsychotic benefits at doses that cause far less D-2 receptor antagonismin the basal ganglia of the brain than that seen with standard neuroleptics; however, newer drugs, such as olanzepine, seroquel and sertindole, are on the way.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 14:39:31